Scarica l'app Stockscreener
95.98
2.98%
2.775
Pre-mercato:
94.95
-1.035
-1.08%
Bright Minds Biosciences Inc Borsa (DRUG) Ultime notizie
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program - TipRanks
Bright Minds prices $175M stock offering - MSN
Bright Minds Biosciences prices public offering at $90 per share By Investing.com - Investing.com India
Bright Minds Biosciences prices $175 million public offering By Investing.com - Investing.com Canada
Bright Minds Biosciences announces pricing of upsized US$175 million public offering of common stock at $90.00 per share - MarketScreener
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock - GlobeNewswire
Bright Minds Biosciences Ends Equity Distribution Deal With Piper Sandler and Cantor - TipRanks
Form FWP BRIGHT MINDS BIOSCIENCES Filed by: BRIGHT MINDS BIOSCIENCES INC. - StreetInsider
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating - Seeking Alpha
Crude Oil Down 2%; ISM Services PMI Surges In December - Benzinga
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Nigeria
Why Did DRUG Stock Rocket 51% Today? - Asianet Newsable
Bright Minds Biosciences falls after $100 mln equity offering launched - TradingView — Track All Markets
Bright Minds Biosciences stock price target raised to $147 by BTIG - Investing.com Nigeria
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Bright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug Pipeline - TipRanks
Will Bright Minds Biosciences Inc. stock deliver shareholder value - ulpravda.ru
Bright Minds Biosciences: Analyzing the Surge - StocksToTrade
Bright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure Disorders - TipRanks
Bright Minds Seizure Treatment Trial Wraps Up - timothysykes.com
Bright Minds Biosciences launches $100 million public offering - MSN
Bright Minds Biosciences launches $100 million public offering By Investing.com - Investing.com India
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering - The Manila Times
Biotech’s $100M cash plan to fund new seizure and rare disease trials - Stock Titan
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Analyzing Bright Minds Biosciences’ Recent Stock Surges - timothysykes.com
Market movers: Bright Mind Biosciences, Sandisk, Under Armour, OPT… - Proactive Investors
Market movers: Bright Mind Biosciences, Sandisk, Under Armour… - Proactive Investors
Bright Minds Stock Surges 22% After Positive Phase 2 Topline Results - Nasdaq
Bright Minds Biosciences (NASDAQ:DRUG) Price Target Raised to $147.00 - MarketBeat
New epilepsy medication from Bright Minds reduces seizures, boosting stock price on Tuesday - Bitget
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday - Benzinga
Bright Minds Biosciences (NASDAQ:DRUG) Hits New 12-Month HighWhat's Next? - MarketBeat
Bright Mind Biosciences shares surge on positive epilepsy drug trial results - Proactive financial news
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why did DRUG stock rocket 51% today? - MSN
Market movers: Bright Mind Biosciences, Sandisk, Under Armour, Digi Power X… - Proactive financial news
Bright Minds reports positive Phase 2 results for epilepsy drug - Investing.com
Bright Minds posts mid-stage trial win for lead drug (DRUG) - Seeking Alpha
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) - The Manila Times
Bright Minds Biosciences stock climbs after positive Phase 2 trial results - Investing.com Canada
DRUG: BMB-101 achieved robust seizure reduction and improved REM sleep in drug-resistant epilepsy - TradingView — Track All Markets
Bright Minds Biosciences Announces Positive Topline Results - GlobeNewswire
Experimental drug sharply cuts hard-to-treat seizures, boosts REM - Stock Titan
(DRUG) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Bright Minds To Unveil Topline Results For BMB-101 Phase 2 Trial In Absence Seizures And DEE - Nasdaq
Bright Minds Biosciences Stock Pre-Market (+10%) : BMB-101 Phase 2 Topline Data Release - Trefis
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Bright Minds Biosciences Sets January 6 Webcast for BMB-101 Phase 2 Topline Results in Drug-Resistant Absence Seizures - TipRanks
Bright Minds to announce topline results for BMB-101 phase 2 trial on Jan 6 - MarketScreener
Bright Minds to report Phase 2 epilepsy drug trial results Tuesday - Investing.com Australia
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - The Manila Times
Bright Minds to report Phase 2 epilepsy drug trial results Tuesday By Investing.com - Investing.com South Africa
New trial results in drug-resistant seizures to be revealed Tuesday - Stock Titan
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 5.7%Time to Sell? - MarketBeat
Bright Minds Biosciences’ (DRUG) Buy Rating Reaffirmed at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
HC Wainwright Has Negative Outlook for DRUG Q1 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% HigherHere's Why - MarketBeat
H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target By Investing.com - Investing.com South Africa
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):